Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

@article{Li2014MetforminSE,
  title={Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal},
  author={L. Li and Rui Han and H. Xiao and C. Lin and Y. Wang and H. Liu and Kunlin Li and Hengyi Chen and Fenfen Sun and Zhenzhou Yang and Jianxin Jiang and Y. He},
  journal={Clinical Cancer Research},
  year={2014},
  volume={20},
  pages={2714 - 2726}
}
Purpose: The EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have become a standard therapy in patients with EGFR-activating mutations. Unfortunately, acquired resistance eventually limits the clinical effects and application of EGFR-TKIs. Studies have shown that suppression of epithelial–mesenchymal transition (EMT) and the interleukin (IL)-6/STAT3 pathway may abrogate this acquired mechanism of drug resistance of TKIs. This study aims to investigate the effect of metformin on sensitizing… Expand
179 Citations

Paper Mentions

Observational Clinical Trial
The third generation epidermal growth factor receptor-tyrosine Kinase Inhibitor(EGFR-TKI) osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID… Expand
ConditionsLung Cancer Non-small Cell Stage IV
InterventionDrug
Observational Clinical Trial
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor(EGFR-TKI) osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID… Expand
ConditionsEGFR T790M, Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
InterventionDrug
Observational Clinical Trial
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor(EGFR-TKI) osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID… Expand
ConditionsEGFR T790M, Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
InterventionDrug
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
  • 15
  • PDF
Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
  • 8
  • PDF
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
  • 42
  • PDF
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
  • 49
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
  • 279
  • PDF
Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
  • 145
  • PDF
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
  • 208
  • PDF
Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
  • 867
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
  • 144
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
  • 45
  • PDF
...
1
2
3
4
5
...